InMed Pharmaceuticals (INM) Operating Income Growth (1y) (2022 - 2025)
InMed Pharmaceuticals (INM) Operating Income Growth (1y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 25.63% |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn | -1.30% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -319.32% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | -14.89% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | 97.23% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | 719.49% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | 21.25% |
| 10 | InMed Pharmaceuticals | 6.92 Mn | 1.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.72% |
| Sep 30, 2025 | -4.94% |
| Jun 30, 2025 | -21.33% |
| Mar 31, 2025 | -3.45% |
| Dec 31, 2024 | -37.03% |
| Sep 30, 2024 | 35.09% |
| Jun 30, 2024 | -319.30% |
| Mar 31, 2024 | 14.29% |
| Dec 31, 2023 | 25.70% |
| Sep 30, 2023 | 25.26% |
| Jun 30, 2023 | 92.56% |
| Mar 31, 2023 | 39.20% |
| Dec 31, 2022 | 48.66% |